Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.09.018
Annals of Surgical Oncology 12:817-824 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takenaka, K.
Right arrow Articles by Tanaka, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takenaka, K.
Right arrow Articles by Tanaka, F.

Original Article

Prognostic Significance of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs Expression in Resected Pathologic Stage IIIA N2 Non–Small-Cell Lung Cancer

Kazumasa Takenaka, MD1, Shinya Ishikawa, MD1, Kazuhiro Yanagihara, MD1, Ryo Miyahara, MD1, Seiki Hasegawa, MD1, Yosuke Otake, MD2, Yoko Morioka, MMed Sci3, Chiaki Takahashi, PhD3, Makoto Noda, PhD3, Harumi Ito, MD4, Hiromi Wada, MD1 and Fumihiro Tanaka, MD1

1 Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 54, Sakyo-ku, Kyoto, 606-8507, Japan
2 Department of Thoracic Surgery, Seishin-Iryo Center Hospital, Kobe, 651-2273, Japan
3 Department of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan
4 Department of Radiology, Faculty of Medicine, University of Fukui, Fukui, 910-1193, Japan

Correspondence: Address correspondence and reprint requests to: Fumihiro Tanaka, MD; E-mail: ftanaka{at}kuhp.kyoto-u.ac.jp.

Background: Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a novel membrane-anchored matrix metalloproteinase inhibitor, and experimental studies have shown that RECK can suppress tumor progression through angiogenesis inhibition. We have already revealed that enhanced RECK expression is significantly correlated with a favorable prognosis in non–small-cell lung cancer (NSCLC). In this study, further analyses focused on pN2 disease were conducted to assess the clinical significance of RECK expression.

Methods: A total of 118 patients with completely resected pathologic stage IIIA N2 NSCLC were retrospectively examined. RECK expression in the primary tumor, along with involved N2 nodes, was examined immunohistochemically.

Results: RECK expression in the primary tumor was strong in 53 patients (44.9%) and was weak in the other 65 patients. The 5-year survival rate of patients with RECK-strong tumor (42.9%) was significantly higher than that of patients with RECK-weak tumor (23.1%; P = .017). Reduced RECK expression significantly correlated with a poor prognosis for patients with a single N2 node involved (P = .019), but not for patients with multiple N2 nodes involved (P = .440). A multivariate analysis confirmed that reduced RECK expression was an independent and significant factor to predict a poor prognosis (P = .031). RECK expression in involved N2 nodes was significantly higher than in primary tumors (P < .001).

Conclusions: RECK status was a novel prognostic factor in pathologic stage IIIA N2 NSCLC.

Key Words: Non–small-cell lung cancer • Stage IIIA • N2 • Prognosis • RECK






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.